EMAIL THIS PAGE TO A FRIEND

Cell death & disease

Targeting Btk/Etk of prostate cancer cells by a novel dual inhibitor.


PMID 25188519

Abstract

Btk and Etk/BMX are Tec-family non-receptor tyrosine kinases. Btk has previously been reported to be expressed primarily in B cells and has an important role in immune responses and B-cell malignancies. Etk has been shown previously to provide a strong survival and metastasis signal in human prostate cancer cells, and to confer androgen independence and drug resistance. While the role of Etk in prostate carcinogenesis is well established, the functions of Btk in prostate cancer have never been investigated, likely due to the perception that Btk is a hematopoietic, but not epithelial, kinase. Herein, we found that Btk is overexpressed in prostate cancer tissues and prostate cancer cells. The level of Btk in prostate cancer tissues correlates with cancer grades. Knockdown of Btk expression selectively inhibits the growth of prostate cancer cells, but not that of the normal prostate epithelial cells, which express very little Btk. Dual inhibition of Btk and Etk has an additive inhibitory effect on prostate cancer cell growth. To explore Btk and Etk as targets for prostate cancer, we developed a small molecule dual inhibitor of Btk and Etk, CTN06. Treatment of PC3 and other prostate cancer cells, but not immortalized prostate epithelial cells with CTN06 resulted in effective cell killing, accompanied by the attenuation of Btk/Etk signals. The killing effect of CTN06 is more potent than that of commonly used inhibitors against Src, Raf/VEGFR and EGFR. CTN06 induces apoptosis as well as autophagy in human prostate cancer cells, and is a chemo-sensitizer for docetaxel (DTX), a standard of care for metastatic prostate cancer patients. CTN06 also impeded the migration of human prostate cancer cells based on a 'wound healing' assay. The anti-cancer effect of CTN06 was further validated in vivo in a PC3 xenograft mouse model.

Related Materials

Product #

Image

Description

Molecular Formula

Add to Cart

270458
1-Methyl-2-pyrrolidinone, for HPLC, ≥99%
C5H9NO
43729
1-Methyl-2-pyrrolidinone, for metal speciation analysis, ≥99.0% (GC)
C5H9NO
M6762
1-Methyl-2-pyrrolidinone
C5H9NO
328634
1-Methyl-2-pyrrolidinone, anhydrous, 99.5%
C5H9NO
494496
1-Methyl-2-pyrrolidinone, biotech. grade, ≥99.7%
C5H9NO
242799
1-Methyl-2-pyrrolidinone, spectrophotometric grade, ≥99%
C5H9NO
443778
1-Methyl-2-pyrrolidinone, ACS reagent, ≥99.0%
C5H9NO
78769
1-Methyl-2-pyrrolidinone, analytical standard
C5H9NO
69118
1-Methyl-2-pyrrolidinone, puriss. p.a., ≥99.0% (GC)
C5H9NO
M79603
1-Methyl-2-pyrrolidinone, ReagentPlus®, 99%
C5H9NO
CDS000967
4-(4-Pyridyl)benzoic acid, AldrichCPR
C12H9NO2
45983
Acetonitrile, analytical standard
C2H3N
PHR1551
Acetonitrile, Pharmaceutical Secondary Standard; Certified Reference Material
C2H3N
00712
Acetonitrile solution, ~20% in H2O, for protein sequence analysis
C2H3N
516961
Ammonium formate, ≥99.995% trace metals basis
CH5NO2
09735
Ammonium formate, BioUltra, ≥99.0% (calc. based on dry substance, NT)
CH5NO2
70221
Ammonium formate, for mass spectrometry, ≥99.0%
CH5NO2
78314
Ammonium formate solution, BioUltra, 10 M in H2O
CH5NO2
714690
Ammonium formate solution, 10 mM in H2O, for HPLC
CH5NO2
481432
Cyanogen bromide, 99.995% trace metals basis
CBrN
16772
Cyanogen bromide, ≥98.5% (RT)
CBrN
C91492
Cyanogen bromide, reagent grade, 97%
CBrN
261610
Cyanogen bromide solution, 5.0 M in acetonitrile
CBrN
341894
Cyanogen bromide solution, 3.0 M in methylene chloride
CBrN
L1002
L-Leucine methyl ester hydrochloride, 98%
C7H15NO2 · HCl
387649
N,N-Diisopropylethylamine, purified by redistillation, 99.5%
C8H19N
496219
N,N-Diisopropylethylamine, 99.5%, biotech. grade
C8H19N
D125806
N,N-Diisopropylethylamine, ReagentPlus®, ≥99%
C8H19N
694134
N-(3-Aminopropyl)piperidine, 95%
C8H18N2
03440
N-Ethyldiisopropylamine, BASF quality, ≥98.0%
C8H19N